Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
(PAR-25-060)
This Notice of Funding Opportunity (NOFO) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this NOFO is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Models proposed for this NOFO would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01 Clinical Trial Not Allowed)
(PAR-25-076)
The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Notice of Funding Opportunity (NOFO) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this NOFO must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP’s NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
(PAR-25-114)
This Notice of Funding Opportunity (NOFO) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids.
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
(PAR-25-130)
The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Notice of Funding Opportunity (NOFO), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.
The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged.
Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
(PAR-24-297)
This notice of funding opportunity (NOFO) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.
Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
(PAR-24-298)
This notice of funding opportunity (NOFO) will support pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services, including: 1) Research in response to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) Research in response to emerging trends and topics related to a change in federal, state, or local drug policy. The work proposed must be related to imminent policy change; 3) Research in response to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 4) Responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug misuse and access and provision of health care service; 5) Research that examines the early implementation of new or newly changed federal, state, or local programs, policy, financing, or payment approaches related to substance use, substance use epidemiology, prevention, treatment, or recovery. Activities may include infrastructure-building partnerships among researchers and state or local organizations to address later implementation phases; 6) Research in response to natural disasters or newly emergent public health emergencies, to understand their impacts on drug markets, substance use epidemiology, prevention, treatment or recovery outcomes.
U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional)
(RFA-AI-24-023)
The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.
Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
(PAR-24-258)
The purpose of this Notice of Funding Opportunity (NOFO) is to support a Human Tissue and Organ Research Resource program to enable the continued availability of human tissues and organs to biomedical researchers. The overall goal of the research resource is to provide a wide variety of human tissues and organs, both diseased and normal, to investigators. The research resource is expected to facilitate the procurement and preservation of human tissues and organs as well as the distribution of these materials to qualified biomedical researchers.
Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)
(PAR-24-273)
The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.
NLM Information Resource Grants to Reduce Health Disparities and Promote Health Equity (G08 Clinical Trial Not Allowed)
(PAR-24-281)
This Notice of Funding Opportunity Announcement (NOFO) solicits resource grant applications for projects that will provide accurate, useful, usable, and understandable health information to populations that experience health disparities and their health care providers. This NOFO supports the development of resources that can be used to improve health and well-being and that lead to reductions in health disparities. Access to accurate, useful, usable, and understandable health information is an important factor when managing health and health care. Proposed projects should harness the capabilities of information technology and medical or health libraries to disseminate clear, evidence-based health-related information in formats used by individuals and their health care providers. Proposed projects should emphasize the development and deployment of new information resources or services, or expand and improve an existing resource or service, to meet the needs of populations experiencing health disparities and to promote health equity.
SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
(PAR-24-263)
The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Innovation Research (SBIR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population genomic screening for common, actionable genomic conditions predominantly in the primary care setting.
NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
(PAR-24-269)
The purpose of the National Institute on Drug Abuse (NIDA) Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie neural and behavioral processes and phenotypes relevant to SUD risk, the SUD trajectory and SUD comorbidities. This opportunity supports research that links genetic, genomic and molecular mechanisms to neural circuit function and behavior. Applications may seek to identify any type of genomic and/or epigenomic variants that contribute to the genetic architecture of addiction, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, data-based, and/or artificial intelligence/machine learning approaches that integrate multi-level ‘omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include variant identification at the circuit level and the application of neuroscience to variant identification studies in tissues and cells. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.
